![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Humanigen’s Lenzilumab Selected for COVID-19 Trial
Humanigen’s Lenzilumab Selected for COVID-19 Trial
![NIH-pic.jpg](https://www.fdanews.com/ext/resources/test/Drug-Images3/NIH-pic.jpg?t=1596147520&width=430)
Humanigen’s monoclonal antibody lenzilumab was selected by the NIH’s National Institutes of Allergy and Infectious Diseases for an upcoming clinical trial of potential COVID-19 therapeutics.
The study will evaluate lenzilumab with remdesivir for treatment of hospitalized COVID-19 patients compared to a placebo and remdesivir. Each arm of the trial will enroll 100 patients.
Lenzilumab is currently in phase 3 testing for preventing and treating cytokine storm leading to acute respiratory distress syndrome.
Upcoming Events
-
21Oct